BSX Stock: Decoding the 2026 Forward Guidance and Core Catalysts

Is the recent sell-off in Boston Scientific (BSX) stock a long-term opportunity, or a sign of deeper structural headwinds? In this video, we break down the critical changes to BSX's official forward guidance for 2026. BSX stock update, Boston Scientific forward guidance, BSX stock analysis, medtech stock catalysts, Boston Scientific Penumbra acquisition, BSX WATCHMAN CHAMPION-AF trial data, Pulsed Field Ablation (PFA) FARAPULSE BSX, medtech investing 2026, Boston Scientific (BSX) earnings update, medical device stock analysis, BSX stock recovery, healthcare stock analysis, BSX share buybacks ASR, Boston Scientific competitive landscape, Boston Scientific (BSX) fundamental analysis The information provided in this video, including all analyses, opinions, and visual representations, is for educational and informational purposes only. It does not constitute financial, investment, legal, or tax advice. We are not financial advisors, nor are we licensed as such. All opinions expressed are our own and are subject to change without notice. No information in this video should be considered a recommendation to buy, sell, or hold any security, including Boston Scientific (BSX) stock. Investing in the stock market involves significant risks, including the potential loss of principal. You are solely responsible for conducting your own due diligence and consulting with a qualified financial professional before making any investment decisions. Past performance is not indicative of future results. We are not liable for any financial losses you may incur as a result of using the information from this video. We may or may not hold a position in BSX stock, which represents a potential conflict of interest.